Drug Patents Expiring in 2027
1. List of Abilify drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(4 years from now) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 07 June, 2006
Treatment: Adjunctive treatment of major depressive disorder (mdd)
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
2. List of Abilify Mycite Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(4 years from now) | |
| US9444503 | OTSUKA | Active signal processing personal health signal receivers |
Nov, 2027
(4 years from now) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Adjunctive treatment of major depressive disorder (mdd); Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patient
Dosage: TABLET;ORAL
3. List of Abraxane drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8034375
(Pediatric) | ABRAXIS BIOSCIENCE | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Dec 6, 2022 |
| Pediatric Exclusivity (PED) | Jun 6, 2023 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: NA
Dosage: POWDER;INTRAVENOUS
4. List of Actoplus Met drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9101660 | TAKEDA PHARMS USA | Solid preparation |
Jan, 2027
(3 years from now) | |
Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 August, 2005
Treatment: NA
Dosage: TABLET;ORAL
5. List of Acular Ls drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8008338 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8008338
(Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2027
(4 years from now) | |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 30 May, 2003
Treatment: A method of treating or preventing ocular pain in a patient
Dosage: SOLUTION/DROPS;OPHTHALMIC
6. List of Adrenaclick drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7905352 | IMPAX | Kits containing medicine injection devices and containers |
Apr, 2027
(4 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 30 May, 2003
Treatment: NA
Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
7. List of Advil Allergy Sinus drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7863287 | GLAXOSMITHKLINE | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines |
Feb, 2027
(4 years from now) | |
Market Authorisation Date: 19 December, 2002
Treatment: NA
Dosage: TABLET;ORAL
8. List of Alsuma drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7811254 | MERIDIAN MEDCL | Autoinjector with needle depth adapter |
Aug, 2027
(4 years from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 29 June, 2010
Treatment: Acute treatment of migraine attacks, with or without aura, and the treatment of cluster headache episodes
Dosage: INJECTABLE;SUBCUTANEOUS
9. List of Altabax drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7875630 | ALMIRALL | Process salts compositions and use |
Feb, 2027
(4 years from now) | |
Drugs and Companies using RETAPAMULIN ingredient
Market Authorisation Date: 12 April, 2007
Treatment: NA
Dosage: OINTMENT;TOPICAL
10. List of Amitiza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8779187 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(3 years from now) | |
| US8338639 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(3 years from now) | |
| US8026393 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Oct, 2027
(4 years from now) | |
Drugs and Companies using LUBIPROSTONE ingredient
Market Authorisation Date: 31 January, 2006
Treatment: NA
Dosage: CAPSULE;ORAL
11. List of Amyvid drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7687052 | AVID RADIOPHARMS INC | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Apr, 2027
(4 years from now) | |
| US8506929 | AVID RADIOPHARMS INC | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Apr, 2027
(4 years from now) | |
Drugs and Companies using FLORBETAPIR F-18 ingredient
Market Authorisation Date: 06 April, 2012
Treatment: Amyvid is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment
Dosage: SOLUTION;INTRAVENOUS
12. List of Anoro Ellipta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7488827 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Dec, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8511304 | GLAXOSMITHKLINE | Medicament dispenser |
Jun, 2027
(4 years from now) | |
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jun 9, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient
Market Authorisation Date: 18 December, 2013
Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.
Dosage: POWDER;INHALATION
13. List of Antizol drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7553863 | PAR PHARM INC | Ultrapure 4-methylpyrazole |
Jun, 2027
(4 years from now) | |
Drugs and Companies using FOMEPIZOLE ingredient
Market Authorisation Date: 04 December, 1997
Treatment: NA
Dosage: INJECTABLE;INJECTION
14. List of Argatroban In Sodium Chloride drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7589106 | EAGLE PHARMS | Alcohol free formulation of argatroban |
Sep, 2027
(4 years from now) | |
| US7687516 | EAGLE PHARMS | Alcohol free formulation of argatroban |
Sep, 2027
(4 years from now) | |
Drugs and Companies using ARGATROBAN ingredient
Market Authorisation Date: 29 June, 2011
Treatment: Method of treating thrombosis; Method of treating an argatroban treatable condition
Dosage: INJECTABLE;INTRAVENOUS
15. List of Arnuity Ellipta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(4 years from now) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 20 August, 2014
Treatment: NA
Dosage: POWDER;INHALATION
16. List of Aubagio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6794410
(Pediatric) | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Mar, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Apr 30, 2024 |
| Pediatric Exclusivity (PED) | Oct 30, 2024 |
Drugs and Companies using TERIFLUNOMIDE ingredient
Market Authorisation Date: 12 September, 2012
Treatment: NA
Dosage: TABLET;ORAL
17. List of Auvi-q drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238108 | KALEO INC | Medicament delivery device having an electronic circuit system |
Feb, 2027
(4 years from now) | |
| US8206360 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2027
(4 years from now) | |
| US9724471 | KALEO INC | Devices, systems, and methods for medicament delivery |
May, 2027
(4 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 10 August, 2012
Treatment: Method for confirming dose delivery
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
18. List of Aveed drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7718640 | ENDO PHARMS INC | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
Mar, 2027
(4 years from now) | |
| US8338395 | ENDO PHARMS INC | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
May, 2027
(4 years from now) | |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 05 March, 2014
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypogonadism (congenital or acquired).
Dosage: INJECTABLE;INTRAMUSCULAR
19. List of Axiron drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8807861 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(4 years from now) | |
| US8419307 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(4 years from now) | |
| US9289586 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(4 years from now) | |
| US8435944 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Sep, 2027
(4 years from now) | |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 23 November, 2010
Treatment: A method of transdermal administration of a physiologically active agent to a subject.; A method of increasing the testosterone blood level of a person in need thereof; A method of increasing the testosterone blood level of an adult male subject in need thereof
Dosage: SOLUTION, METERED;TRANSDERMAL
20. List of Azilect drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7815942 | TEVA | Rasagiline formulations of improved content uniformity |
Aug, 2027
(4 years from now) | |
Drugs and Companies using RASAGILINE MESYLATE ingredient
Market Authorisation Date: 16 May, 2006
Treatment: Treatment of parkinson's disease
Dosage: TABLET;ORAL
21. List of Balcoltra drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7838042 | AVION PHARMS | Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions |
Jun, 2027
(4 years from now) | |
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 09 January, 2018
Treatment: Administration of ferrous bisglycinate tablets
Dosage: TABLET;ORAL
22. List of Belbuca drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9655843 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
| US8147866 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 October, 2015
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Treatement of pain by transmucosal delivery of buprenorphine
Dosage: FILM;BUCCAL
23. List of Beleodaq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835501 | ACROTECH | Pharmaceutical formulations of HDAC inhibitors |
Oct, 2027
(4 years from now) | |
Drugs and Companies using BELINOSTAT ingredient
Market Authorisation Date: 03 July, 2014
Treatment: NA
Dosage: POWDER;INTRAVENOUS
24. List of Breo Ellipta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8511304 | GLAXO GRP LTD | Medicament dispenser |
Jun, 2027
(4 years from now) | |
| US9333310 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8113199 | GLAXO GRP LTD | Counter for use with a medicament dispenser |
Oct, 2027
(4 years from now) | |
Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient
Market Authorisation Date: 10 May, 2013
Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; Long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations
Dosage: POWDER;INHALATION
25. List of Bunavail drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8147866 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
| US9655843 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: Maintenance treatment of opioid dependence; Treatment of opioid dependence
Dosage: FILM;BUCCAL
26. List of Bydureon drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8329648
(Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(4 years from now) | |
|
US8906851
(Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(4 years from now) | |
|
US9884092
(Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(4 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(4 years from now) | |
| US8758292 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Nov, 2027
(4 years from now) | |
|
US8501698
(Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jul 22, 2024 |
| M | Feb 15, 2022 |
| Pediatric Exclusivity (PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
27. List of Bydureon Bcise drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9884092
(Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(4 years from now) | |
|
US8906851
(Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(4 years from now) | |
|
US8329648
(Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(4 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(4 years from now) | |
|
US8501698
(Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jul 22, 2024 |
| M | Feb 15, 2022 |
| Pediatric Exclusivity (PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin
Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
28. List of Byfavo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9914738 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
| US9777007 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
| US10961250 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
| US10472365 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 6, 2025 |
Drugs and Companies using REMIMAZOLAM BESYLATE ingredient
NCE-1 date: October, 2024
Market Authorisation Date: 06 October, 2020
Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less
Dosage: POWDER;INTRAVENOUS
29. List of Byvalson drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7838552 | ALLERGAN | Compositions comprising nebivolol |
Oct, 2027
(4 years from now) | |
Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient
Market Authorisation Date: 03 June, 2016
Treatment: Method of treating hypertension
Dosage: TABLET;ORAL
30. List of Cabenuva Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11389447 | VIIV HLTHCARE | Aqueous suspensions of TMC278 |
Jun, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 21, 2026 |
| New Patient Population (NPP) | Mar 29, 2025 |
| New Dosing Schedule (D) | Jan 31, 2025 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
31. List of Camcevi Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9744207 | ACCORD | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(3 years from now) | |
| US10646572 | ACCORD | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(3 years from now) | |
| US9572857 | ACCORD | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | May 25, 2024 |
Drugs and Companies using LEUPROLIDE MESYLATE ingredient
Market Authorisation Date: 25 May, 2021
Treatment: NA
Dosage: EMULSION;SUBCUTANEOUS
32. List of Cardene drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8455524 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(4 years from now) | |
| US7659291 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(4 years from now) | |
| US10758616 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(4 years from now) | |
| US7612102 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(4 years from now) | |
| US9364564 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(4 years from now) | |
Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 1992
Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof
Dosage: INJECTABLE;INJECTION; INJECTABLE;INTRAVENOUS
33. List of Chloraprep One-step drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7422388 | BECTON DICKINSON CO | Applicator for coloring antiseptic |
Apr, 2027
(4 years from now) | |
Drugs and Companies using CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL ingredient
Market Authorisation Date: 14 July, 2000
Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery
Dosage: SPONGE;TOPICAL
34. List of Chlorhexidine Gluconate drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7935093 | SAGE PRODS | Disinfectant delivery system and method of providing alcohol-free disinfection |
Oct, 2027
(4 years from now) | |
Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient
Market Authorisation Date: 25 April, 2005
Treatment: For the preparation of skin prior to surgery; Helps reduce bacteria that can potentially cause skin infection
Dosage: CLOTH;TOPICAL
35. List of Colazal drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7452872
(Pediatric) | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Feb, 2027
(4 years from now) | |
|
US7625884
(Pediatric) | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Feb, 2027
(4 years from now) | |
Drugs and Companies using BALSALAZIDE DISODIUM ingredient
Market Authorisation Date: 18 July, 2000
Treatment: NA
Dosage: CAPSULE;ORAL
36. List of Combivent Respimat drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(4 years from now) | |
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
37. List of Contrave drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9107837 | NALPROPION | Sustained release formulation of naltrexone |
Jun, 2027
(4 years from now) | |
| US9125868 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(4 years from now) | |
| US10307376 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(4 years from now) | |
| US8722085 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(4 years from now) | |
| US8318788 | NALPROPION | Layered pharmaceutical formulations |
Nov, 2027
(4 years from now) | |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity; Use of naltrexone and bupropion based on an escalating dose schedule; Use of naltrexone and bupropion in a layered formulation for chronic weight management for affecting weight loss
Dosage: TABLET, EXTENDED RELEASE;ORAL
38. List of Corlanor drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7867996
(Pediatric) | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Jun, 2027
(4 years from now) | |
Drugs and Companies using IVABRADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 April, 2015
Treatment: NA
Dosage: TABLET;ORAL
39. List of Cotellic drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8362002
(Pediatric) | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Apr, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 10, 2022 |
| New Indication (I) | Oct 28, 2025 |
| M | Jul 28, 2025 |
| Pediatric Exclusivity (PED) | Jan 28, 2026 |
Drugs and Companies using COBIMETINIB FUMARATE ingredient
Market Authorisation Date: 10 November, 2015
Treatment: NA
Dosage: TABLET;ORAL
40. List of Cresemba drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10206879 | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Sep, 2027
(4 years from now) | |
| US10603280 | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Sep, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 6, 2020 |
| Orphan Drug Exclusivity (ODE) | Mar 6, 2022 |
| Generating Antibiotic Incentives Now (GAIN) | Mar 6, 2027 |
Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient
NCE-1 date: March, 2026
Market Authorisation Date: 06 March, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
41. List of Daklinza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9421192 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(4 years from now) | |
| US8642025 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8900566 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(4 years from now) | |
Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient
Market Authorisation Date: 24 July, 2015
Treatment: Method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity; Method of inhibiting hepatitis c virus
Dosage: TABLET;ORAL
42. List of Dexilant drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7790755
(Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Feb, 2027
(4 years from now) | |
|
US8105626
(Pediatric) | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Mar, 2027
(4 years from now) | |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE;ORAL
43. List of Dificid drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7378508 | CUBIST PHARMS LLC | Polymorphic crystalline forms of tiacumicin B |
Jul, 2027
(4 years from now) | |
| US7863249 | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7906489 | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Mar, 2027
(4 years from now) | |
| US7863249 | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(4 years from now) | |
| US8859510 | CUBIST PHARMS LLC | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(4 years from now) | |
|
US7906489
(Pediatric) | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Sep, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jan 24, 2023 |
| Orphan Drug Exclusivity (ODE) | Jan 24, 2027 |
| Pediatric Exclusivity (PED) | Jul 24, 2023 |
Drugs and Companies using FIDAXOMICIN ingredient
Market Authorisation Date: 27 May, 2011
Treatment: Treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older; Treatment of microbial infections
Dosage: TABLET;ORAL
44. List of Dovato drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Combination (NC) | Apr 8, 2022 |
| New Indication (I) | Aug 6, 2023 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 08 April, 2019
Treatment: NA
Dosage: TABLET;ORAL
45. List of Dsuvia drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9744129 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US8252329 | ACELRX PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(3 years from now) | |
| US9320710 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US8226978 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US8865211 | ACELRX PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(3 years from now) | |
| US10245228 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US10507180 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US8252328 | ACELRX PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(3 years from now) | |
| US8778394 | ACELRX PHARMS | Small-volume oral transmucosal dosage forms |
Jan, 2027
(3 years from now) | |
| US8535714 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US8778393 | ACELRX PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(3 years from now) | |
| US8231900 | ACELRX PHARMS | Small-volume oral transmucosal dosage |
Jan, 2027
(3 years from now) | |
| US10342762 | ACELRX PHARMS | Small-volume oral transmucosal dosage forms |
Jan, 2027
(3 years from now) | |
Drugs and Companies using SUFENTANIL CITRATE ingredient
Market Authorisation Date: 02 November, 2018
Treatment: Treatment of acute pain
Dosage: TABLET;SUBLINGUAL
46. List of Duaklir Pressair drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8051851 | ASTRAZENECA | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Combination (NC) | Mar 29, 2022 |
Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient
Market Authorisation Date: 29 March, 2019
Treatment: NA
Dosage: POWDER, METERED;INHALATION
47. List of Duavee drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7683051 | WYETH PHARMS | Crystalline polymorph of bazedoxifene acetate |
Mar, 2027
(4 years from now) | |
Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient
Market Authorisation Date: 03 October, 2013
Treatment: Prevention of postmenopausal osteoporosis; Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: TABLET;ORAL
48. List of Duetact drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7700128 | TAKEDA PHARMS USA | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
Jan, 2027
(4 years from now) | |
Drugs and Companies using GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 July, 2006
Treatment: NA
Dosage: TABLET;ORAL
49. List of Durysta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8206737 | ALLERGAN INC | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
Apr, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 4, 2023 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 04 March, 2020
Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant
Dosage: IMPLANT;OPHTHALMIC
50. List of Dyanavel Xr drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10086087 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(4 years from now) | |
| US8883217 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(4 years from now) | |
| US8597684 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(4 years from now) | |
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(4 years from now) | |
| US9675703 | TRIS PHARMA INC | Modified release formulations containing drug - ion exchange resin complexes |
Mar, 2027
(4 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 19 October, 2015
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
51. List of Dyanavel Xr 10 drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8337890 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(4 years from now) | |
| US9675704 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(4 years from now) | |
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(4 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
52. List of Dyloject drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8946292 | JAVELIN PHARMS INC | Formulations of low dose diclofenac and beta-cyclodextrin |
Mar, 2027
(4 years from now) | |
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 23 December, 2014
Treatment: Management of pain
Dosage: SOLUTION;INTRAVENOUS
53. List of Edluar drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9597281 | MYLAN SPECIALITY LP | Pharmaceutical formulations useful in the treatment of insomnia |
Apr, 2027
(4 years from now) | |
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 13 March, 2009
Treatment: Method of treating insomnia characterized by difficulty with sleep onset
Dosage: TABLET;SUBLINGUAL
54. List of Elepsia Xr drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8163306 | TRIPOINT | Oral drug delivery system |
Sep, 2027
(4 years from now) | |
| US8431156 | TRIPOINT | Pharmaceutical composition |
Oct, 2027
(4 years from now) | |
| US8470367 | TRIPOINT | Oral drug delivery system |
Oct, 2027
(4 years from now) | |
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 20 December, 2018
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
55. List of Embeda drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7682633 | ALPHARMA PHARMS | Pharmaceutical composition |
Jun, 2027
(4 years from now) | |
| US8158156 | ALPHARMA PHARMS | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
Jun, 2027
(4 years from now) | |
| US8846104 | ALPHARMA PHARMS | Pharmaceutical compositions for the deterrence and/or prevention of abuse |
Jun, 2027
(4 years from now) | |
| US8877247 | ALPHARMA PHARMS | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
Jun, 2027
(4 years from now) | |
| US7682634 | ALPHARMA PHARMS | Pharmaceutical compositions |
Jun, 2027
(4 years from now) | |
| US7815934 | ALPHARMA PHARMS | Sequestering subunit and related compositions and methods |
Dec, 2027
(4 years from now) | |
Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 August, 2009
Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatement by orally administering an intact composition as claimed.
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
56. List of Emend drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MSD MERCK CO | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(4 years from now) | |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 17 December, 2015
Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)
Dosage: FOR SUSPENSION;ORAL
57. List of Emend drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MERCK | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(4 years from now) | |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 26 March, 2003
Treatment: Prevention of postoperative nausea and vomiting; For the prevention of nausea and vomiting associated with chemotherapy
Dosage: CAPSULE;ORAL
58. List of Empaveli drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9169307 | APELLIS PHARMS | Potent compstatin analogs |
Nov, 2027
(4 years from now) | |
| US7989589 | APELLIS PHARMS | Compstatin analogs with improved activity |
Dec, 2027
(4 years from now) | |
| US7888323 | APELLIS PHARMS | Potent compstatin analogs |
Dec, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 14, 2026 |
| Orphan Drug Exclusivity (ODE) | May 14, 2028 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: May, 2025
Market Authorisation Date: 14 May, 2021
Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of complement inhibitor pegcetacoplan
Dosage: SOLUTION;SUBCUTANEOUS
59. List of Entresto drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8877938 | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
May, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9388134
(Pediatric) | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
May, 2027
(4 years from now) | |
|
US8877938
(Pediatric) | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
Nov, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Oct 1, 2022 |
| M | Feb 16, 2024 |
| Pediatric Exclusivity (PED) | Apr 1, 2023 |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
Market Authorisation Date: 07 July, 2015
Treatment: NA
Dosage: TABLET;ORAL
60. List of Epiduo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8445543 | GALDERMA LABS LP | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
Jul, 2027
(4 years from now) | |
| US8071644 | GALDERMA LABS LP | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
Jul, 2027
(4 years from now) | |
| US8129362 | GALDERMA LABS LP | Combination/association of adapalene and benzoyl peroxide for treating acne lesions |
Jul, 2027
(4 years from now) | |
| US8080537 | GALDERMA LABS LP | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
Jul, 2027
(4 years from now) | |
Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient
Market Authorisation Date: 08 December, 2008
Treatment: Treatment of acne
Dosage: GEL;TOPICAL
61. List of Erleada drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9388159 | JANSSEN BIOTECH | Substituted diazaspiroalkanes as androgen receptor modulators |
Mar, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802689 | JANSSEN BIOTECH | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
Mar, 2027
(4 years from now) | |
| US9987261 | JANSSEN BIOTECH | Substituted diazaspiroalkanes as androgen receptor modulators |
Mar, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 14, 2023 |
| New Indication (I) | Sep 17, 2022 |
Drugs and Companies using APALUTAMIDE ingredient
NCE-1 date: February, 2022
Market Authorisation Date: 14 February, 2018
Treatment: Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment of metastatic castration-sensitive prostate cancer (mcspc)
Dosage: TABLET;ORAL
62. List of Esbriet drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7767700 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(4 years from now) | |
| US8420674 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(4 years from now) | |
| US7696236 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(4 years from now) | |
Drugs and Companies using PIRFENIDONE ingredient
Market Authorisation Date: 15 October, 2014
Treatment: Pirfenidone dose escalation regimen for treatment of ipf as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen; Pirfenidone dose escalation regimen for treatment of fibrosis as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen; Dose escalation over 14 days for treatment of idiopathic pulmonary fibrosis
Dosage: CAPSULE;ORAL
63. List of Eucrisa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501712 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(4 years from now) | |
| US9682092 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(4 years from now) | |
|
US8501712
(Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(4 years from now) | |
|
US9682092
(Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Mar 23, 2023 |
| Pediatric Exclusivity (PED) | Jun 14, 2022 |
Drugs and Companies using CRISABOROLE ingredient
Market Authorisation Date: 14 December, 2016
Treatment: Method of treating mild to moderate atopic dermatitis.
Dosage: OINTMENT;TOPICAL
64. List of Evzio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238108 | KALEO INC | Medicament delivery device having an electronic circuit system |
Feb, 2027
(4 years from now) | |
| US8206360 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2027
(4 years from now) | |
| US9724471 | KALEO INC | Devices, systems, and methods for medicament delivery |
May, 2027
(4 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: Method for confirming dose delivery
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
65. List of Evzio (autoinjector) drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238108 | KALEO INC | Medicament delivery device having an electronic circuit system |
Feb, 2027
(4 years from now) | |
| US8206360 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2027
(4 years from now) | |
| US9724471 | KALEO INC | Devices, systems, and methods for medicament delivery |
May, 2027
(4 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: Method for confirming dose delivery
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
66. List of Fanapt drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8586610 | VANDA PHARMS INC | Methods for the administration of iloperidone |
Nov, 2027
(4 years from now) | |
Drugs and Companies using ILOPERIDONE ingredient
Market Authorisation Date: 06 May, 2009
Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are poor metabolizers of cyp2d6
Dosage: TABLET;ORAL
67. List of Farxiga drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Feb 22, 2022 |
| New Indication (I) | Oct 18, 2022 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
Market Authorisation Date: 08 January, 2014
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET;ORAL
68. List of Fibricor drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7741373 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(4 years from now) | |
| US7569612 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(4 years from now) | |
| US7915247 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(4 years from now) | |
| US7741374 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(4 years from now) | |
Drugs and Companies using FENOFIBRIC ACID ingredient
Market Authorisation Date: 14 August, 2009
Treatment: Adjunctive therapy to diet to patients with hypertriglyceridemia; Adjunctive therapy to diet in patients with hyperlipidemias; Adjunctive therapy to diet in patients with mixed dyslipidemia; Adjunctive therapy to diet in patients with elevated cholesterol and/or lipid levels
Dosage: TABLET;ORAL
69. List of Finacea drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7700076 | LEO PHARMA AS | Penetrating pharmaceutical foam |
Sep, 2027
(4 years from now) | |
| US10117812 | LEO PHARMA AS | Foamable composition combining a polar solvent and a hydrophobic carrier |
Oct, 2027
(4 years from now) | |
| US9265725 | LEO PHARMA AS | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
Dec, 2027
(4 years from now) | |
Drugs and Companies using AZELAIC ACID ingredient
Market Authorisation Date: 29 July, 2015
Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea
Dosage: AEROSOL, FOAM;TOPICAL
70. List of Flolipid drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10300041 | TCG FLUENT PHARMA | Liquid oral simvastatin compositions |
Apr, 2027
(4 years from now) | |
Drugs and Companies using SIMVASTATIN ingredient
Market Authorisation Date: 21 April, 2016
Treatment: NA
Dosage: SUSPENSION;ORAL
71. List of Forfivo Xl drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7674479 | ALMATICA | Sustained-release bupropion and bupropion/mecamylamine tablets |
Jun, 2027
(4 years from now) | |
Drugs and Companies using BUPROPION HYDROCHLORIDE ingredient
Market Authorisation Date: 10 November, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
72. List of Galafold drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9987263 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(4 years from now) | |
| US9000011 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(4 years from now) | |
| US10383864 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(4 years from now) | |
| US10406143 | AMICUS THERAP US | Methods for treatment of fabry disease |
May, 2027
(4 years from now) | |
| US11241422 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(4 years from now) | |
| US9480682 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity (ODE) | Aug 10, 2025 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients
Dosage: CAPSULE;ORAL
73. List of Genosyl drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7560076 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Apr, 2027
(4 years from now) | |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 20 December, 2019
Treatment: NA
Dosage: GAS;INHALATION
74. List of Genvoya drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7176220
(Pediatric) | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Feb, 2027
(4 years from now) | |
|
US8981103
(Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(4 years from now) | |
|
US7635704
(Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(4 years from now) | |
Market Authorisation Date: 05 November, 2015
Treatment: NA
Dosage: TABLET;ORAL
75. List of Gilenya drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9187405 | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Jun, 2027
(4 years from now) | |
|
US9187405
(Pediatric) | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Dec, 2027
(4 years from now) | |
| US10543179 | NOVARTIS | Dosage regimen of an S1P receptor modulator |
Dec, 2027
(4 years from now) | |
Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient
Market Authorisation Date: 21 September, 2010
Treatment: Treatment of relapsing-remitting sclerosis (ms); Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment
Dosage: CAPSULE;ORAL
76. List of Gilotrif drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9539258
(Pediatric) | BOEHRINGER INGELHEIM | Quinazoline derivatives for the treatment of cancer diseases |
May, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jan 12, 2025 |
| M | Apr 7, 2025 |
| Pediatric Exclusivity (PED) | Oct 15, 2023 |
Drugs and Companies using AFATINIB DIMALEATE ingredient
Market Authorisation Date: 12 July, 2013
Treatment: NA
Dosage: TABLET;ORAL
77. List of Glyxambi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(4 years from now) | |
| US11033552 | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
May, 2027
(4 years from now) | |
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jul 3, 2022 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
Market Authorisation Date: 30 January, 2015
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin
Dosage: TABLET;ORAL
78. List of Halaven drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE46965 | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jan, 2027
(3 years from now) | |
|
USRE46965
(Pediatric) | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jul, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jan 28, 2023 |
| M | Sep 13, 2025 |
| Pediatric Exclusivity (PED) | Mar 13, 2026 |
Drugs and Companies using ERIBULIN MESYLATE ingredient
Market Authorisation Date: 15 November, 2010
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
79. List of Hysingla Er drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9095614 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9545380 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9492391 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9492390 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9763933 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9095615 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9770416 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9486413 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9084816 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9486412 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9775809 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US9492389 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US11304909 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
| US11304908 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
Drugs and Companies using HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 20 November, 2014
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: TABLET, EXTENDED RELEASE;ORAL
80. List of Ibrance drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE47739 | PFIZER | 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones |
Mar, 2027
(4 years from now) | |
Drugs and Companies using PALBOCICLIB ingredient
Market Authorisation Date: 03 February, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
81. List of Iclusig drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8114874 | TAKEDA PHARMS USA | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors |
Jan, 2027
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Dec 18, 2023 |
Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient
Market Authorisation Date: 14 December, 2012
Treatment: NA
Dosage: TABLET;ORAL
82. List of Iluvien drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8871241 | ALIMERA SCIENCES INC | Injectable sustained release delivery devices |
Aug, 2027
(4 years from now) | |
Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient
Market Authorisation Date: 26 September, 2014
Treatment: NA
Dosage: IMPLANT;INTRAVITREAL
83. List of Imbruvica drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8008309 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Nov, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8563563 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Apr, 2027
(4 years from now) | |
|
US8476284
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8703780
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8754091
(Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8735403
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8697711
(Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton'S tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8497277
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US9181257
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8957079
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8952015
(Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US7514444
(Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8563563
(Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Oct, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jan 25, 2022 |
| New Patient Population (NPP) | Aug 24, 2025 |
| Pediatric Exclusivity (PED) | Feb 24, 2026 |
Drugs and Companies using IBRUTINIB ingredient
Market Authorisation Date: 16 February, 2018
Treatment: Treatment of small lymphocytic lymphoma; Treatment of chronic small lymphocytic leukemia; Treatment of waldenstrom's macroglobulinemia; Treatment of chronic lymphocytic leukemia
Dosage: TABLET;ORAL
84. List of Imcivree drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8039435 | RHYTHM | Melanocortin receptor ligands |
Oct, 2027
(4 years from now) | |
| US9458195 | RHYTHM | Melanocortin receptor ligands |
Oct, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 25, 2027 |
| New Chemical Entity Exclusivity (NCE) | Nov 25, 2025 |
| New Indication (I) | Jun 16, 2025 |
Drugs and Companies using SETMELANOTIDE ACETATE ingredient
NCE-1 date: November, 2024
Market Authorisation Date: 25 November, 2020
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
85. List of Implanon drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10821277 | ORGANON | Kit for and method of assembling an applicator for inserting an implant |
May, 2027
(4 years from now) | |
| US8722037 | ORGANON | X-ray visible drug delivery device |
Sep, 2027
(4 years from now) | |
Drugs and Companies using ETONOGESTREL ingredient
Market Authorisation Date: 17 July, 2006
Treatment: NA
Dosage: IMPLANT;IMPLANTATION
86. List of Incruse Ellipta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7488827 | GLAXO GRP ENGLAND | Muscarinic acetylcholine receptor antagonists |
Dec, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9333310 | GLAXO GRP ENGLAND | Medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8113199 | GLAXO GRP ENGLAND | Counter for use with a medicament dispenser |
Oct, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jun 9, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE ingredient
Market Authorisation Date: 30 April, 2014
Treatment: NA
Dosage: POWDER;INHALATION
87. List of Ingrezza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8357697 | NEUROCRINE | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
Nov, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 11, 2022 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
NCE-1 date: April, 2021
Market Authorisation Date: 11 April, 2017
Treatment: Treatment of tardive dyskinesia
Dosage: CAPSULE;ORAL
88. List of Injectafer drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11478502 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
| US11433091 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
| US8895612 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Strength (NS) | Apr 28, 2024 |
| New Patient Population (NPP) | Nov 19, 2024 |
Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient
Market Authorisation Date: 25 July, 2013
Treatment: Method to treat ida in adults with intolerance or unsatisfactory response to oral iron & heavy uterine bleeding or gi disorder weighing at least 40 kg by administering iv ferric carboxymaltose to give at least 0.6 g of iron in 15 minutes or less; Method to treat iron deficiency anemia in adults with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least 0.6 g of elemental iron in 15 minutes or less; Method to treat iron deficiency anemia in adults with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least 0.6 g of elemental iron in 15 minutes or less; Method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 46.7 kg by intravenously administering ferric carboxymaltose to provide at least 0.7 g of elemental iron in 15 minutes; Method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 46.7 kg by intravenously administering ferric carboxymaltose to provide at least 0.7 g of elemental iron in less than 15 minutes; Method to treat ida in adults & pediatric patients 1 year & older with intolerance or unsatisfactory response to oral iron & heavy uterine bleeding or gi disorder by administering iv ferric carboxymaltose to give at least 0.7 g of iron in 15 minutes; Method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 46.7 kg by administering iv ferric carboxymaltose to provide at least 0.7 g of elemental iron in < 15 minutes; Method of treatment of iron-related conditions with at least 0.6 grams of elemental iron via an iron carbohydrate complex, with a substantially non-immunogenic carbohydrate component, in about 15 minutes or less.; Method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering at least about 0.6g of iron as ferric carboxymaltose in about 15 min or less; Method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering at least about 0.6g of iron as ferric carboxymaltose in about 15 min or less; Method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering about 1 g of iron as ferric carboxymaltose in about 15 minutes or less; Method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering about 1 g of iron as ferric carboxymaltose in about 15 minutes or less; Method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by administering iv at least about 0.6 g of iron as ferric carboxymaltose in about 15 min or less; Method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering at least about 0.6 grams of iron as ferric carboxymaltose in about 15 minutes or less
Dosage: SOLUTION;INTRAVENOUS
89. List of Intermezzo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7658945 | PURDUE PHARMA | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
Apr, 2027
(4 years from now) | |
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 23 November, 2011
Treatment: Method for treating insomnia
Dosage: TABLET;SUBLINGUAL
90. List of Invokamet drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(4 years from now) | |
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(4 years from now) | |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 08 August, 2014
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients
Dosage: TABLET;ORAL
91. List of Invokamet Xr drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(4 years from now) | |
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(4 years from now) | |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 20 September, 2016
Treatment: Treatment of type 2 diabetes mellitus; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients
Dosage: TABLET, EXTENDED RELEASE;ORAL
92. List of Invokana drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(4 years from now) | |
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Sep 27, 2022 |
Drugs and Companies using CANAGLIFLOZIN ingredient
Market Authorisation Date: 29 March, 2013
Treatment: Treatment of type 2 diabetes mellitus; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients
Dosage: TABLET;ORAL
93. List of Jakafi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7598257 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Dec, 2027
(4 years from now) | |
| US8415362 | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9079912
(Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Jun, 2027
(4 years from now) | |
|
US9814722
(Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Jun, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Sep 22, 2024 |
| Orphan Drug Exclusivity (ODE) | Sep 22, 2028 |
| Pediatric Exclusivity (PED) | Nov 24, 2026 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
Market Authorisation Date: 16 November, 2011
Treatment: For treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; For treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf
Dosage: TABLET;ORAL
94. List of Janumet drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7326708
(Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Aug 12, 2022 |
| Pediatric Exclusivity (PED) | Jun 4, 2024 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 30 March, 2007
Treatment: NA
Dosage: TABLET;ORAL
95. List of Janumet Xr drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7326708
(Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Dec 4, 2023 |
| Pediatric Exclusivity (PED) | Jun 4, 2024 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 02 February, 2012
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
96. List of Januvia drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7326708
(Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Dec 4, 2023 |
| Pediatric Exclusivity (PED) | Feb 12, 2023 |
Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 16 October, 2006
Treatment: NA
Dosage: TABLET;ORAL
97. List of Jardiance drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Aug 18, 2024 |
| M | Feb 24, 2025 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
Market Authorisation Date: 01 August, 2014
Treatment: NA
Dosage: TABLET;ORAL
98. List of Jatenzo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11331325 | CLARUS | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
Jan, 2027
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 27, 2022 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 27 March, 2019
Treatment: Method of treating testosterone deficiency
Dosage: CAPSULE;ORAL
99. List of Jentadueto drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jul 3, 2022 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 2012
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin
Dosage: TABLET;ORAL
100. List of Jentadueto Xr drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(4 years from now) | |
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jul 3, 2022 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 May, 2016
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin
Dosage: TABLET, EXTENDED RELEASE;ORAL
101. List of Juluca drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(4 years from now) | |
Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 November, 2017
Treatment: NA
Dosage: TABLET;ORAL
102. List of Juxtapid drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7932268 | AMRYT | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Aug, 2027
(4 years from now) | |
Drugs and Companies using LOMITAPIDE MESYLATE ingredient
Market Authorisation Date: 21 December, 2012
Treatment: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses
Dosage: CAPSULE;ORAL
103. List of Kalydeco drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7495103 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324242 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Aug, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 21, 2027 |
| New Patient Population (NPP) | Apr 29, 2022 |
Drugs and Companies using IVACAFTOR ingredient
Market Authorisation Date: 17 March, 2015
Treatment: Method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide; Method of treating cystic fibrosis; Treatment of cystic fibrosis using ivacaftor in a patient age 6 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; Treatment of cystic fibrosis using ivacaftor in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data
Dosage: GRANULE;ORAL
104. List of Kalydeco drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7495103 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
May, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324242 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Aug, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 21, 2027 |
Drugs and Companies using IVACAFTOR ingredient
Market Authorisation Date: 31 January, 2012
Treatment: Method of treating cystic fibrosis; Method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide
Dosage: TABLET;ORAL
105. List of Karbinal Er drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9522191 | AYTU | Modified release formulations containing drug—ion exchange resin complexes |
Jun, 2027
(4 years from now) | |
Drugs and Companies using CARBINOXAMINE MALEATE ingredient
Market Authorisation Date: 28 March, 2013
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
106. List of Klisyri drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10323001 | ALMIRALL | Compositions for modulating a kinase cascade and methods of use thereof |
Dec, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 14, 2025 |
Drugs and Companies using TIRBANIBULIN ingredient
NCE-1 date: December, 2024
Market Authorisation Date: 14 December, 2020
Treatment: NA
Dosage: OINTMENT;TOPICAL
107. List of Korsuva drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10017536 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(4 years from now) | |
| US8536131 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(4 years from now) | |
| US7402564 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| US7713937 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(4 years from now) | |
| US10793596 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| US7727963 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8236766 | CARA THERAP | Uses of synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| US8217007 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| US8486894 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(4 years from now) | |
| US10138270 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| US9334305 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(4 years from now) | |
| US9359399 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 23, 2026 |
Drugs and Companies using DIFELIKEFALIN ACETATE ingredient
NCE-1 date: August, 2025
Market Authorisation Date: 23 August, 2021
Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)
Dosage: SOLUTION;INTRAVENOUS
108. List of Kybella drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7622130 | KYTHERA BIOPHARMS | Methods and compositions for the non-surgical removal of fat |
Dec, 2027
(4 years from now) | |
| US7754230 | KYTHERA BIOPHARMS | Methods and related compositions for reduction of fat |
Dec, 2027
(4 years from now) | |
Drugs and Companies using DEOXYCHOLIC ACID ingredient
Market Authorisation Date: 29 April, 2015
Treatment: Method for reduction of submental fat
Dosage: SOLUTION;SUBCUTANEOUS
109. List of Kynamro drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7511131 | KASTLE THERAPS LLC | Antisense modulation of apolipoprotein B expression |
Jan, 2027
(3 years from now) | |
Drugs and Companies using MIPOMERSEN SODIUM ingredient
Market Authorisation Date: 29 January, 2013
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
110. List of Kyprolis drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7737112 | ONYX THERAP | Composition for enzyme inhibition |
Dec, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Aug 20, 2023 |
Drugs and Companies using CARFILZOMIB ingredient
Market Authorisation Date: 20 July, 2012
Treatment: NA
Dosage: POWDER;INTRAVENOUS
111. List of Lastacaft drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10617695 | ALLERGAN | Ophthalmic compositions containing alcaftadine |
Mar, 2027
(4 years from now) | |
| US8664215 | ALLERGAN | Ocular allergy treatments with alcaftadine |
Dec, 2027
(4 years from now) | |
Drugs and Companies using ALCAFTADINE ingredient
Market Authorisation Date: 28 July, 2010
Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
Dosage: SOLUTION/DROPS;OPHTHALMIC
112. List of Lenvima drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9006256 | EISAI INC | Antitumor agent for thyroid cancer |
Jul, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 15, 2025 |
| New Indication (I) | Aug 10, 2024 |
| M | Dec 19, 2024 |
Drugs and Companies using LENVATINIB MESYLATE ingredient
Market Authorisation Date: 13 February, 2015
Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer
Dosage: CAPSULE;ORAL
113. List of Leqvio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8809292 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
May, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222222 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
Dec, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: December, 2025
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene
Dosage: SOLUTION;SUBCUTANEOUS
114. List of Letairis drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8377933 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(4 years from now) | |
| US9474752 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(4 years from now) | |
Drugs and Companies using AMBRISENTAN ingredient
Market Authorisation Date: 15 June, 2007
Treatment: For the treatment of pulmonary hypertension (pah) in combination with tadalafil
Dosage: TABLET;ORAL
115. List of Levitra drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8273876 | BAYER HLTHCARE | Medicaments containing vardenafil hydrochloride trihydrate |
Jul, 2027
(4 years from now) | |
Drugs and Companies using VARDENAFIL HYDROCHLORIDE ingredient
Market Authorisation Date: 19 August, 2003
Treatment: Treatement of erectiile dysfunction by administering a film-coated tablet
Dosage: TABLET;ORAL
116. List of Lexiscan drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8106183 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47301 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(4 years from now) | |
Drugs and Companies using REGADENOSON ingredient
Market Authorisation Date: 10 April, 2008
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
117. List of Lumigan drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7851504 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Jun, 2027
(4 years from now) | |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 31 August, 2010
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
118. List of Lynparza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071579 | ASTRAZENECA | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(4 years from now) | |
| US8143241 | ASTRAZENECA | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | May 8, 2027 |
| New Indication (I) | Mar 11, 2025 |
Drugs and Companies using OLAPARIB ingredient
Market Authorisation Date: 17 August, 2017
Treatment: Maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen; Treatment of hr-positive, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, and with endocrine therapy or are inappropriate for endocrine therapy; Maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; Treatment of deleterious or suspected deleterious germline brca-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy; Treatment of hr-negative, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; Maintenance treatment of brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; Maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; Treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Maintenance treatment of gbrca- or sbrca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; Maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; Maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; Maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Adjuvant treatment of patients with gbrca-mutated human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy; Treatment of brca mutated ovarian cancer using parp inhibitor
Dosage: TABLET;ORAL
119. List of Lyrica Cr drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10022447
(Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(4 years from now) | |
|
US8945620
(Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(4 years from now) | |
|
US9144559
(Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(4 years from now) | |
Drugs and Companies using PREGABALIN ingredient
Market Authorisation Date: 11 October, 2017
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
120. List of Macrilen drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8192719 | NOVO | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds |
Oct, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 20, 2024 |
| New Chemical Entity Exclusivity (NCE) | Dec 20, 2022 |
Drugs and Companies using MACIMORELIN ACETATE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 20 December, 2017
Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin
Dosage: FOR SOLUTION;ORAL
121. List of Mekinist drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7378423 | NOVARTIS | Pyrimidine compound and medical use thereof |
May, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 22, 2024 |
| M | Oct 6, 2022 |
| New Indication (I) | Jun 22, 2025 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
Market Authorisation Date: 29 May, 2013
Treatment: NA
Dosage: TABLET;ORAL
122. List of Moxatag drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8299052 | PRAGMA | Pharmaceutical compositions and methods for improved bacterial eradication |
May, 2027
(4 years from now) | |
Drugs and Companies using AMOXICILLIN ingredient
Market Authorisation Date: 23 January, 2008
Treatment: Use of once-a-day amoxicillin product to treat tonsillitis and/or pharyngitis secondary to streptococcus pyogenes
Dosage: TABLET, EXTENDED RELEASE;ORAL
123. List of Neupro drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8246979 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Sep, 2027
(4 years from now) | |
Drugs and Companies using ROTIGOTINE ingredient
Market Authorisation Date: 09 May, 2007
Treatment: Treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system; Treatment of restless legs syndrome by application of claimed transdermal delivery system
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL